1. Home
  2. KOPN vs LPTX Comparison

KOPN vs LPTX Comparison

Compare KOPN & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KOPN
  • LPTX
  • Stock Information
  • Founded
  • KOPN 1984
  • LPTX 2011
  • Country
  • KOPN United States
  • LPTX United States
  • Employees
  • KOPN N/A
  • LPTX N/A
  • Industry
  • KOPN Semiconductors
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • KOPN Technology
  • LPTX Health Care
  • Exchange
  • KOPN Nasdaq
  • LPTX Nasdaq
  • Market Cap
  • KOPN 138.4M
  • LPTX 119.6M
  • IPO Year
  • KOPN 1992
  • LPTX N/A
  • Fundamental
  • Price
  • KOPN $1.28
  • LPTX $0.38
  • Analyst Decision
  • KOPN Strong Buy
  • LPTX Buy
  • Analyst Count
  • KOPN 4
  • LPTX 2
  • Target Price
  • KOPN $2.56
  • LPTX $8.00
  • AVG Volume (30 Days)
  • KOPN 2.3M
  • LPTX 283.3K
  • Earning Date
  • KOPN 05-13-2025
  • LPTX 05-13-2025
  • Dividend Yield
  • KOPN N/A
  • LPTX N/A
  • EPS Growth
  • KOPN N/A
  • LPTX N/A
  • EPS
  • KOPN N/A
  • LPTX N/A
  • Revenue
  • KOPN $50,841,018.00
  • LPTX N/A
  • Revenue This Year
  • KOPN $8.53
  • LPTX N/A
  • Revenue Next Year
  • KOPN $20.42
  • LPTX N/A
  • P/E Ratio
  • KOPN N/A
  • LPTX N/A
  • Revenue Growth
  • KOPN 28.16
  • LPTX N/A
  • 52 Week Low
  • KOPN $0.56
  • LPTX $0.22
  • 52 Week High
  • KOPN $2.17
  • LPTX $4.79
  • Technical
  • Relative Strength Index (RSI)
  • KOPN 46.73
  • LPTX 48.68
  • Support Level
  • KOPN $1.30
  • LPTX $0.35
  • Resistance Level
  • KOPN $1.45
  • LPTX $0.40
  • Average True Range (ATR)
  • KOPN 0.11
  • LPTX 0.04
  • MACD
  • KOPN -0.02
  • LPTX 0.00
  • Stochastic Oscillator
  • KOPN 0.00
  • LPTX 53.70

About KOPN Kopin Corporation

Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

Share on Social Networks: